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Abstract
Background: Abdominal aortic aneurysm (AAA) is a slowly progressive destructive process of the main abdominal
artery. Experimental studies indicate that fibrates exert beneficial effects on AAAs by mechanisms involving both
serum lipid modification and favourable changes to the AAA wall.
Methods/design: Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME) is a multicentre,
randomised, double-blind, placebo-controlled clinical trial to assess the effect of orally administered therapy with
fenofibrate on key pathological markers of AAA in patients undergoing open AAA repair. A total of 42 participants
scheduled for an elective open AAA repair will be randomly assigned to either 145 mg of fenofibrate per day or
identical placebo for a minimum period of 2 weeks prior to surgery. Primary outcome measures will be
macrophage number and osteopontin (OPN) concentration within the AAA wall as well as serum concentrations of
OPN. Secondary outcome measures will include levels of matrix metalloproteinases and proinflammatory cytokines
within the AAA wall, periaortic fat and intramural thrombus and circulating concentrations of AAA biomarkers.
Discussion: At present, there is no recognised medical therapy to limit AAA progression. The FAME trial aims to
assess the ability of fenofibrate to alter tissue markers of AAA pathology.
Trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12612001226897. Registered on 20
November 2012.
Keywords: Abdominal aortic aneurysm, Fenofibrate, Clinical trial, Osteopontin, Macrophage
Background
An abdominal aortic aneurysm (AAA) is defined as a
progressive dilation of the infrarenal aorta, and is associ-
ated with a risk of fatal rupture which increases at larger
AAA diameters [1, 2]. The incidence of AAA increases
with advancing age, with approximately 5% of men and
approximately 1% of women aged over 65 years having
an AAA [3–7]. Other risk factors include smoking,
hypertension, Caucasian ethnicity and a positive family
history [8, 9]. Small AAAs (30–54 mm in diameter) are
typically asymptomatic and may be detected as an
incidental finding on imaging performed for other
purposes, or as a pulsatile abdominal mass on routine
physical examination. AAA screening programmes using
ultrasound have been introduced in the United Kingdom,
the United States and Sweden and are expected to reduce
aneurysm-related mortality [10–13]. There is no recog-
nised medical therapy for AAAs, with current manage-
ment comprising regular ultrasound surveillance, until a
diameter threshold is reached (typically 55 mm), at which
point surgical repair is considered as the risk of aortic
rupture is considered to be high for most patients [14].
Identification of an effective drug therapy to limit
AAA progression would represent a significant advance-
ment in clinical management. Clinical trials in humans
have yet to report convincing benefit of any tested agent
in slowing AAA growth [15–18]. However, preclinical
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studies continue to hold promise. Studies employing two
rodent models reported that the peroxisome proliferator
activator alpha (PPARα) ligand fenofibrate can reduce
AAA development [19, 20]. Notably, in one study,
fenofibrate-mediated protection against AAA formation
was associated with the concomitant reduction of the
proinflammatory protein osteopontin (OPN) and reduced
recruitment of macrophages to the aortic wall [19]. Osteo-
pontin (OPN) is a phosphorylated acidic glycoprotein that
is implicated in many processes integral to AAA devel-
opment including inflammation, proteolysis and ath-
erosclerosis [21–26]. OPN deficiency has been shown to
protect against AAA formation in angiotensin-II-infused
apolipoprotein-e-deficient mice [27], and serum OPN has
been shown to be independently associated with AAA
presence and growth in humans [28]. Of significant im-
portance to the development and progression of AAA in
experimental models is the ability of OPN to promote
macrophage accumulation within the aorta [27, 29]. Mac-
rophages are implicated in aortic destruction as a result of
the production of a range of proteolytic enzymes, such as
matrix metalloproteinases (MMPs) [30], and marked
macrophage infiltration is a consistent feature of human
AAA [31].
PPARα ligands have been shown to downregulate OPN
expression in human macrophages in vitro [32]. Fibrates
are well-known PPARα ligands and are indicated in the
treatment of hypertriglyceridemia [33]. Previous studies in
rodent models suggest that fenofibrate downregulates
OPN expression in hypertrophied left ventricle and dys-
functional renal cells [34, 35]. Furthermore, treatment of
diabetic patients with bezafibrate for 4 weeks has been
shown to reduce circulating concentrations of OPN by ap-
proximately 40% [32]. The ability of fenofibrate to down-
regulate OPN may be critical in reducing macrophage
infiltration and the associated release of proteolytic en-
zymes, thus potentially limiting AAA expansion. Addition-
ally, fenofibrate is known to elevate serum high-density
lipoprotein (HDL) which has been associated with protec-
tion from AAA [31].
Collectively, the above findings lead to the hypothesis
that a short course of fenofibrate will exert beneficial ef-
fects on AAA by mechanisms involving both serum lipid
modification and favourable changes to the AAA wall.
The aim of the current study is to assess the effect of
fenofibrate taken daily for a minimum of 2 weeks in par-
ticipants scheduled for elective open AAA repair. This
group of patients is particularly suitable since the AAA
will be replaced with a prosthetic graft enabling the AAA
wall and thrombus to be removed for biological assessment.
The primary aim of the study is to determine whether feno-
fibrate will reduce the relative number of AAA-wall macro-
phages, reduce the relative concentration of AAA-wall
OPN and also reduce the serum concentrations of OPN.
The effect of fenofibrate on secondary parameters, includ-
ing inflammatory cell (neutrophils, B-and T-lymphocytes)
number, MMPs and proinflammatory cytokines within the
AAA wall, periaortic fat and intramural thrombus, and
circulating concentrations of AAA biomarkers, includ-
ing osteoprotegerin, resistin, D-dimer and fasting lipids,
will also be assessed [31, 36–38].
Methods/design
Study design and participants
Fenofibrate in the management of AbdoMinal aortic
anEurysm (FAME) is a multicentre, randomised, double-
blind, placebo-controlled clinical trial to assess the effect
of orally administered therapy with fenofibrate on key
pathological markers of AAA in patients undergoing
open AAA repair. The trial will be conducted at four
sites in Australia: The Royal Brisbane and Women’s
Hospital, Brisbane; The Holy Spirit Northside Private
Hospital, Brisbane; The Townsville Hospital, Townsville
and The Mater Hospital, Townsville. The trial will be
reported according to the Standard Protocol Items:
Recommendations for Intervention Trials (SPIRIT) (see
Additional files 1 and 2). Only research personnel who
are directly involved in the recruitment and data collec-
tion aspect of the study will have access to patients’
personal details. All Case Report Forms (CRFs), source
documentation and samples will be stored de-identified
where personal information has been removed and
coded with a study number.
The FAME trial will include participants recruited
from specialist vascular outpatient clinics who have an
asymptomatic infrarenal AAA with a maximum orthog-
onal diameter ≥50 mm. FAME will not include individ-
uals who require emergency or urgent AAA repair due
to the requirement for a minimum 2 weeks of treatment
with trial medication prior to surgery. Furthermore, par-
ticipants will only be included if it is determined that
they have a high likelihood of treatment compliance ac-
cording to the treating physician or local study coordinator.
Additional exclusion criteria include current treatment with
fibrates, known contraindications to fenofibrate treatment
and previous aortic surgery. A full list of inclusion and
exclusion criteria is given in Table 1.
Randomisation and follow-up
The overall design of the FAME trial is shown in Fig. 1.
At the initial visit, potential participants booked for an
elective open repair of an AAA will be assessed against the
eligibility criteria (Table 1) and, if appropriate, informed
consent will be obtained. Individuals will undergo a
medical examination, resting blood pressure and heart
rate assessments, and collection of blood samples for
measurement of full blood count (haemoglobin, white cell
count, platelets, neutrophils, lymphocytes, monocytes,
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eosinophils, basophils), urea and electrolytes (sodium,
potassium, creatinine, estimated glomerular filtration
rate, urea, chloride, bicarbonate), liver function tests
(Albumin, total bilirubin, alanine transaminase, aspartate
aminotransferase, gamma-glutamyl transpeptidase, lactate
dehydrogenase), fasting lipids (cholesterol, triglyceride,
HDL cholesterol, low-density lipoprotein (LDL) choles-
terol), fasting glucose and C-reactive protein. Serum,
plasma and whole blood will also be collected for the
later assessment of circulating concentrations of protein
(such as cytokines) and genetic (deoxyribonucleic acid
(DNA) and ribonucleic acid (RNA)) markers. Investiga-
tional blood samples will be collected into the following
tubes: 2 × 5-mL SST, 2 × 4-mL EDTA tubes, 1 × 4-mL so-
dium citrate tube and 1 × 2.5-mL PaxGene tube. Blood
samples will be processed according to site-specific stand-
ard operating procedures (SOPs) and shipped to the study
centre in Townsville. Eligible participants will be rando-
mised to receive 145 mg fenofibrate or placebo, admin-
istered once a day for a minimum of 2 weeks directly
prior to surgery, in a parallel-group design. Random-
isation to fenofibrate or placebo will be stratified by
study centre. Random allocation sequences will be
computer-generated by a statistician and provided to
each study centre's clinical trial pharmacist, ensuring
both investigators and participants are blinded to drug
assignment. Trial medication will be allocated and
dispensed by the local study centre’s clinical trials
pharmacist. Allocation concealment will be achieved
by using identical packaging of the intervention and
placebo. In the case of an emergency situation where
breaking of the group allocation blinding would be
required, the local study centre clinical trial pharma-
cist will be contacted. To facilitate compliance, partic-
ipants will be provided with the phone number of the
local study coordinator with instructions to contact
them in the event of possible medication-related prob-
lems or consideration of discontinuation. In this event
arrangements will be made for the participant to be
reviewed by the study physician to ascertain whether
discontinuation is required.
Table 1 Patient eligibility criteria
Inclusion criteria
• Ability to provide written informed consent
• Diagnosis with an asymptomatic AAA which is infrarenal in location
and measures ≥50 mm on CTA
• Scheduled for an elective open repair of an AAA
• High likelihood of medication compliance within the 2-week period
prior to surgery
Exclusion criteria
• Currently taking fenofibrate or related fibrates
• Contraindication to fenofibrate treatment:
o Liver impairment as demonstrated by abnormal AST or ALT tests
(>1.5 × ULN)
o Renal impairment as demonstrated by an elevated serum creatinine
level (>150 μM)
o Symptomatic gallbladder disease
o Previous reaction to any lipid-modifying medication
• Previous infrarenal abdominal aortic surgery
• Mycotic AAA
• Requirement for emergency or urgent open AAA repair
• Current participation in another drug trial
CTA computed tomographic angiography, AAA abdominal aortic aneurysm,
AST aspartate aminotransferase, ALT alanine transaminase, ULN upper limit
of normal
Fig. 1 Schematic diagram of the Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME) trial
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On the day of surgery, further blood samples will be
collected (as per initial visit). Adverse and clinical events
will be recorded, changes to usual medication noted,
and compliance with the study drug regimen analysed
by capsule counting. During open surgery, biopsies will
be taken from the following sites: (1) subcutaneous fat at
the incision site, (2) periaortic fat near the AAA, (3)
AAA neck, (4) AAA body (opposite the inferior mesen-
teric artery) and (5) AAA thrombus. To preserve RNA
and protein integrity, tissue samples will be collected
into liquid nitrogen immediately upon harvest for subse-
quent genetic and protein analysis. An additional AAA
body sample will be collected and immediately stored in
10% (v/v) paraformaldehyde and wax-embedded for im-
munohistochemical analysis. All collection of tissues will
be performed according to site-specific SOPs and shipped
to the study centre in Townsville.
Outcome assessment
Outcome assessment will be performed at the study
centre in Townsville on the tissue and blood samples
collected. All outcome assessment will be conducted by
scientists blinded to the treatment allocation of the
participants.
Primary outcome assessment
To assess AAA-wall macrophage number, serial cryostat
sections 7 μm thick will be cut from each AAA wall
sample for subsequent macrophage staining, as previ-
ously described [19]. All samples will be stained simul-
taneously using identical reagents and incubation times.
Serial frozen sections will be air-dried, fixed in acetone
for 10 min at −20 °C, air-dried and rehydrated with
phosphate-buffered saline (PBS) before being incubated
in 3% H2O2/0.1% sodium azide/PBS to block endogen-
ous peroxidase. For macrophage detection, sections will
be blocked in 2% (v/v) normal goat serum in PBS followed
by staining using pan-macrophage antibody (Abcam) and
goat anti-rat HRP (Chemicon). An IgG (Sigma) will be
used as isotype control. Slides will be incubated in the per-
oxidase substrate 3,3’-diaminobenzidine (ImmPACT DAB,
Vector Laboratories), counterstained in Mayer’s haema-
toxylin, dehydrated, cleared in xylene and mounted in
Depex mounting medium. Stained sections will be photo-
graphed using a Leica BMLB microscope fitted with a
SPOTTM CCD Camera (Diagnostic Instruments, Inc.,
Sterling Heights, MI, USA) and digital images captured to
a PC supported with SPOT32TM software (version 2.1.2;
Diagnostic Instruments, Inc., Sterling Heights, MI, USA).
Identical exposure times and settings will be used for sec-
tions. Image analysis will be performed on digital tiff im-
ages using Adobe Photoshop CS6 Extended software. For
each section, the total tissue area and area of macrophage
staining will be measured using the ‘Selection Tool’ and
‘Record Measurements’ functions. Macrophage staining
will be expressed as macrophage number and also as a
percentage of total tissue area.
AAA-wall OPN will be determined using an enzyme-
linked immunosorbent assay (ELISA) and immunohisto-
chemistry. For determination by ELISA, protein will be
extracted from individual frozen AAA wall biopsies by
homogenising in buffer (10 mM cacodylic acid, 60 mM L-
arginine, 0.25% (v/v) Triton x-100 in PBS, pH 7.2) and
centrifuging at 18,000 × g at 4 °C for 20 min. Supernatant
protein will be quantified by the Bradford technique
(Protein Assay, Bio-Rad, Hercules, CA, USA). OPN
concentration will be measured by ELISA (Quantikine,
R&D Systems for OPN) and expressed as pg/mg of
protein. Excellent reproducibility of similar assays has
previously been reported [39]. For determination by
immunohistochemistry, slides will be incubated in 2%
(v/v) normal goat serum (Vector Laboratories) in PBS
and endogenous avidin and biotin-blocked using an
Avidin/Biotin blocking kit (Vector Laboratories), then
2 μg/mL rabbit anti-human OPN (Immuno Biological
Laboratories), biotinylated goat anti-rabbit IgG (Vector
Laboratories) and Vectastain Elite ABC-HRP. Rabbit
IgG (Vector Laboratories) will be used as isotype con-
trol antibody.
Serum OPN concentration will be measured using
blood collected from participants following an overnight
fast. Serum will be stored at −80 °C until later batch as-
sessment using ELISA according to the manufacturer’s
instructions, and expressed as ng/mL (R&D Systems).
This assay has previously demonstrated excellent intra-
and inter-assay reproducibility [39].
Secondary outcome assessment
Additionally, inflammatory cells (neutrophils, B- and T-
lymphocytes), MMPs and proinflammatory cytokines
will be assessed by immunohistochemistry and ELISA as
previously described [40, 41]. Circulating concentrations
of other AAA biomarkers, including osteoprotegerin,
resistin, D-dimer and fasting lipids, will be assessed by
ELISA and automated assays as previously described
[31, 36–38]. Whole genome microarrays and real-time
polymerase chain reaction will be used to examine gene
expression levels based on findings from ongoing ex-
pression arrays and biomarker studies.
Study population and power calculation
Estimated outcomes for the control group are based on
assessments performed in human AAA biopsies or blood
samples from previous studies [28, 32, 42–44]. Estimated
effect sizes for fenofibrate therapy are based on previous
rodent and human studies, and the consideration of
outcomes likely to be required for clinical efficacy
[19, 28, 32, 42–44]. To significantly influence the natural
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history of aortic destruction, it is estimated that a reduc-
tion in all primary outcomes assessed within AAA biop-
sies of at least 50% is likely to be required. In a rodent
model, 4 weeks’ treatment with fenofibrate reduced aortic
OPN concentration and macrophage infiltration by a me-
dian of 95% and 70%, respectively, suggesting that this
treatment effect size is realistic [19]. For serum OPN, it
has previously been reported that a fibrate reduced circu-
lating OPN concentration by approximately 40% after
4 weeks of treatment [32]. Based on these data, the esti-
mated mean values for control and treatment groups were
calculated and are given in Table 2. Sample sizes were cal-
culated using GPower3.1, based on a t test as the statistical
analysis test. Since there are three primary outcomes,
alpha was set at .017, adjusted from .05 for multiple test-
ing. Sample size was estimated based on a power of 80%
and equal numbers of participants in each treatment arm.
As a result, 20 participants receiving fenofibrate and 20
participants receiving placebo are required. Assuming a
dropout rate of 5%, a total of 42 participants will be
required.
Safety
Participant safety will be assessed prior to the adminis-
tration of the medication and at the end of the study
period. At the initial visit, a consultation with a phys-
ician will occur, during which the participant will be in-
formed about known side effects including symptoms of
abdominal/back pain, chest pain, and renal and liver dys-
function. Pathology tests consisting of full blood count,
fasting lipids, glucose, inflammation markers, liver and
renal function will be performed. The participant will
undergo a physical assessment which will include blood
pressure and heart rate measurements that will be
reviewed by a physician along with the results of pathology
tests prior to randomisation. At the final visit, pathology
tests as per the initial visit will be performed and reviewed
by a physician. Any adverse event will be reported to the
coordinating centre and carefully monitored throughout
the study. Serious adverse events (SAEs) will be defined as
death, requirement for inpatient hospital treatment and
persistent or significant disability. All SAEs will be re-
ported by the site principle investigator to the HREC
and reviewed by the chief principle investigator, where
a decision regarding withdrawal of trial medication
will be made. Where a decision to withdraw trial medica-
tion is made, participants will be encouraged to remain on
the study protocol. Previous studies suggest that fenofi-
brate is a relatively safe medication [45, 46]. Participants
who are concurrently on warfarin will have two additional
safety assessments after randomisation. Current routine
care for patients on warfarin involves ongoing measure-
ment of International Normalised Ratio (INR) levels,
which in turn dictates the dose of medication required
to manage clotting without increasing the risk of exces-
sive bleeding. Participants will be instructed to have
their INR concentrations assessed via their usual sys-
tem at 3–5 days and again at 14–21 days post first dose
so that warfarin dosage may be adjusted accordingly.
Data management and analysis
Trial documentation including protocols, SOPs and CRFs
will be shared electronically with participating study cen-
tres. Protocol amendments will be submitted to the Royal
Brisbane and Women’s Hospital HREC and local site re-
search governance offices and disseminated to the relevant
parties at each study site. Data recorded on printed CRFs
will be scanned to the study centre in Townsville where it
will be entered centrally and examined for data quality.
This will allow confirmation of entry criteria and collec-
tion of set entry and outcome data. Examples of important
baseline data which will be collected include age, gender,
presence of diabetes and/or dyslipidaemia, concurrent
medications and maximum aortic diameter. At comple-
tion of the trial the database will be checked for errors and
data confirmed with source documentation where re-
quired. Analysis of primary and secondary endpoints will
be based on intention-to-treat at the time of randomisa-
tion. All participants who meet the eligibility criteria, pro-
vide written informed consent and are enrolled in the
study will be included in the primary analysis, regardless
of adherence to medication allocation.
To identify potential confounders, collected clinical
and demographic data will be compared between groups
via univariate statistics. The distribution of all continu-
ous data variables will be assessed for normality using
the Kolgorov-Smirnov test. Normally distributed con-
tinuous variables will be compared between test groups
via t test; non-normally continuous distributed variables
will be compared between groups using the Mann-
Whitney U test. Nominal data will be compared using the
chi-squared test. Characteristics showing a p value < 0.100
on univariate tests will be considered as potential con-
founders and will be entered as covariates in subsequent








ELISA 210 ± 145 84 ± 87
AAA-wall macrophages
(per mm2 section)
IHC 4.9 ± 1.8 2.4 ± 1.8
Serum OPN concentration
(ng/mL)
ELISA 77 ± 32 46 ± 32
AAA abdominal aortic aneurysm, ELISA enzyme-linked immunosorbent assay,
IHC immunohistochemistry, OPN osteopontin
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binary logistic regression models assessing the association
of each of the outcome measures with treatment alloca-
tion. Following binary logistic regression, the association
of all covariates with treatment allocation will be reported
as odds ratios and 95% confidence intervals. For all ana-
lyses, p values <0.05 will be considered to be significant.
Data will be published in a peer-reviewed journal with
copies of the paper available to participants if required.
Discussion
The estimated global prevalence rate of AAA per 100,000
in 2010 has been reported to range from approximately 8
in individuals aged 40–44 years to approximately 2,275 in
individuals aged 75–79 years [47]. Prevalence is reported
to be higher in developed versus developing nations, and
in 2010 was highest in Australasia [47]. The global death
rate due to AAA per 100,000 has been reported to have
increased from 2.49 in 1990 to 2.78 in 2010, with the high-
est mean death rate found to occur in Australasia [48]. At
present there is no known effective medical therapy to
limit AAA progression, and large randomised trials have
failed to provide evidence that early elective endovascular
repair (EVAR) or open surgery for patients with AAAs
measuring 40–54 mm reduces mortality [49–52]. Current
management of patients with small AAAs involves regular
repeat imaging since most small AAAs slowly increase in
size, with approximately 70% of 40–54-mm AAAs requir-
ing surgical repair [49–53]. AAA surgery is associated with
significant mortality (1–5%) and perioperative complica-
tions (approximately 20%) [50, 52, 54, 55]. Whilst EVAR
has gained popularity in recent years due to reduced
length of inpatient stay and reduced intensive care unit
admissions, total hospital costs are significantly greater
than those associated with open repair (approximately
AU$23,000 versus approximately AU$18,500 for preopera-
tive, operative, postoperative and 1-year follow-up costs)
in part due to the requirement for lifelong surveillance
and the high rate of need for reintervention [54].
In the current study the effect of a promising new
medical therapy will be assessed to determine whether a
short course of fenofibrate will inhibit AAA-OPN ex-
pression and associated macrophage-based inflamma-
tion, whilst inducing other potential beneficial effects
such as raising HDL.
Trial status
At the time of submission, recruitment was ongoing.
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